This page lists the cancer care hospitals in our directory offering Liver Cancer Treatment in Dubai, UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about liver cancer treatment in Dubai, UAE
Share a few details and our care coordination team will get back to you with next steps.
Compare 3 accredited hospitals for Cancer Care in Dubai, UAE
Featured🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Ranks #1 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Kings College Hospital Dubai
Ranks #2 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Aster Hospital Dubai
Ranks #3 in this list by listed rating (4.5/5 from 1 reviews).
How we selected these hospitals
A hospital appears on this page when Cancer Care is among its listed specialties and it is located in Dubai, UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Liver Cancer Treatment in Dubai, UAE?
Choosing the right hospital for liver cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cancer care rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Liver Cancer Treatment
Liver cancer treatment encompasses a spectrum of advanced interventions — from hepatic resection and liver transplantation to locoregional therapies such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and systemic targeted therapy — achieving curative or long-term disease-control outcomes in carefully selected patients. Internationally recognized oncology centers in India and the UAE report 5-year survival rates of 60–70% for early-stage hepatocellular carcinoma (HCC) managed with curative intent, placing them on par with leading Western institutions at a fraction of the cost. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, providing end-to-end coordination so patients can focus entirely on their recovery. Hospital Stay: 7–21 days (varies by modality: 3–5 days for ablative procedures; 14–21 days for major hepatic resection or transplantation) • Total Stay in Country (Fit-to-Fly): 3–8 weeks (3–4 weeks post-ablation or TACE; 6–8 weeks post-major resection or transplant, pending hepatic function recovery and surgical wound assessment) • Success Rate: 60–70% 5-year survival for early-stage (Barcelona Clinic Liver Cancer Stage 0/A); 30–40% for intermediate-stage with locoregional therapy
Clinical Overview
Liver cancer — most commonly hepatocellular carcinoma (HCC), which accounts for approximately 75–85% of all primary liver malignancies — arises from hepatocytes within a background of chronic liver disease, viral hepatitis (HBV/HCV), alcohol-related cirrhosis, or non-alcoholic steatohepatitis (NASH). HCC is the sixth most common cancer worldwide and the third leading cause of cancer-related death, underscoring the urgent need for expert, multidisciplinary management. The tumor disrupts hepatic parenchymal architecture, impairing the liver's critical functions — detoxification, protein synthesis (albumin, clotting factors), bile production, and glycogen storage — leading to progressive hepatic insufficiency, portal hypertension, and systemic complications including ascites, variceal bleeding, and hepatic encephalopathy. The Barcelona Clinic Liver Cancer (BCLC) staging system is the globally accepted framework for treatment allocation, stratifying patients by tumor burden, liver functional reserve (Child-Pugh and ALBI scores), and performance status (ECOG scale). Early-stage disease (BCLC 0/A) is managed with curative modalities — surgical resection, percutaneous ablation, or liver transplantation within Milan or UCSF criteria. Intermediate-stage disease (BCLC B) is treated with TACE or transarterial radioembolization (TARE/Y-90), while advanced-stage disease (BCLC C) is now addressed with increasingly potent systemic agents. The standard of care has evolved significantly with the 2020 approval of the atezolizumab + bevacizumab (Tecentriq + Avastin) combination as the first-line regimen for advanced HCC, superseding sorafenib in most patients. Leading oncology centers in India and the UAE deploy the full spectrum of these modalities under a Multidisciplinary Tumor Board (MDT) model that integrates hepatobiliary surgery, interventional radiology, medical oncology, hepatology, and radiation oncology. Robotic-assisted hepatectomy using the Da Vinci Surgical System, real-time intraoperative ultrasound guidance, and stereotactic body radiation therapy (SBRT) for select patients represent the cutting edge of care available at GAF Healthcare's partner institutions, ensuring that international patients receive a standard of treatment equivalent to — and often indistinguishable from — major academic centers in North America or Europe.
Who is a Candidate?
• ELIGIBLE PATIENTS (Curative Intent): • Solitary HCC ≤5 cm or up to 3 nodules each ≤3 cm with preserved liver function (Child-Pugh A or select Child-Pugh B) — eligible for surgical resection or ablation • HCC within Milan criteria (single tumor ≤5 cm, or ≤3 tumors each ≤3 cm, no vascular invasion, no extrahepatic spread) — eligible for liver transplantation (living-donor or deceased-donor) • HCC within UCSF criteria — may be considered for transplant at select high-volume centers • Performance status ECOG 0–1 with adequate cardiopulmonary reserve for surgical candidates • Hepatitis B/C-related HCC with controlled viral load on antiviral therapy • ELIGIBLE PATIENTS (Locoregional / Palliative Intent): • Intermediate-stage HCC (BCLC B): multifocal disease without vascular invasion or extrahepatic spread — eligible for TACE or Y-90 TARE • Tumors not amenable to surgery due to location, size, or compromised hepatic reserve — eligible for RFA, microwave ablation (MWA), or cryoablation • Advanced-stage HCC (BCLC C) with portal vein tumor thrombus or distant metastases — eligible for systemic therapy (atezolizumab + bevacizumab; sorafenib; lenvatinib; regorafenib second-line) • Downstaging candidates: patients with intermediate/advanced HCC who may achieve Milan criteria after locoregional therapy, subsequently transitioning to transplant evaluation • REQUIRED PRE-TREATMENT DIAGNOSTICS: • Dynamic contrast-enhanced MRI of the liver (preferred) or 4-phase CT scan — primary HCC diagnosis per LI-RADS criteria (LI-RADS 5 = definitive HCC without biopsy) • Serum alpha-fetoprotein (AFP), AFP-L3 fraction, and des-gamma-carboxyprothrombin (DCP/PIVKA-II) • Liver function tests: Child-Pugh score, MELD score, albumin-bilirubin (ALBI) grade • Indocyanine green (ICG) retention test (15-minute clearance rate) — critical for surgical resection planning • PET-CT scan (F-18 FDG or C-11 Acetate) for extrahepatic staging and detection of poorly differentiated HCC • Liver volumetry (CT-based) for future liver remnant (FLR) calculation prior to major hepatectomy; portal vein embolization (PVE) considered if FLR < 30–40% • Upper GI endoscopy for variceal assessment; echocardiography (ECHO) for transplant candidates • Hepatitis B surface antigen, anti-HCV antibody, HBV DNA, HCV RNA quantification • Tissue biopsy (18G core needle, ultrasound-guided) for non-classic imaging appearances or when enrollment in clinical trials is planned • CONTRAINDICATIONS / UNFAVORABLE INDICATORS: • Decompensated cirrhosis (Child-Pugh C) with refractory ascites, hepatic encephalopathy, or recurrent variceal bleeding — generally ineligible for major resection or systemic therapy • Diffuse bilobar HCC with extensive portal vein tumor thrombus (PVTT) involving the main portal trunk — high-risk for hepatic failure post-TACE • Severe portal hypertension (hepatic venous pressure gradient >10 mmHg) — relative contraindication to resection • Active uncontrolled systemic infection • Unresolved esophageal varices at high risk of bleeding prior to initiation of bevacizumab-based therapy • Significant renal impairment or severe cardiovascular disease precluding contrast-based imaging or systemic therapy
Treatment Options & Approaches
SURGICAL APPROACHES: 1. Hepatic Resection (Hepatectomy): The gold-standard curative treatment for patients with solitary or oligofocal HCC and well-preserved liver function. Anatomic resection (removal of a defined hepatic segment or lobe) is preferred over non-anatomic wedge resection as it encompasses the portal territories supplying the tumor, reducing intrahepatic recurrence. Major hepatectomy (≥3 Couinaud segments) requires careful preoperative volumetric assessment and ICG testing. Robotic-assisted hepatectomy (Da Vinci Xi System) offers superior 3D magnification, tremor filtration, and articulating instruments for resections near the hepatic veins and inferior vena cava — reducing blood loss, transfusion requirements, and length of stay compared to open surgery. Laparoscopic hepatectomy is offered for peripheral, anterolateral-segment tumors. Intraoperative ultrasound (IOUS) with real-time contrast enhancement guides margin assessment. 2. Liver Transplantation: The only treatment that simultaneously removes the tumor and the underlying cirrhotic liver, addressing both the malignancy and the field defect that predisposes to recurrence. Outcomes are excellent for patients within Milan criteria (5-year survival >70%). Living-donor liver transplantation (LDLT) is a strength of leading Indian centers, where large volumes of LDLT reduce waiting times significantly compared to deceased-donor programs. Immunosuppression post-transplant uses calcineurin inhibitors (tacrolimus-based protocols) with mTOR inhibitors (everolimus) introduced for their potential anti-tumor properties. LOCOREGIONAL THERAPIES: 3. Transarterial Chemoembolization (TACE): The reference standard for intermediate-stage HCC. Conventional TACE (cTACE) delivers a mixture of lipiodol + chemotherapeutic agent (doxorubicin or cisplatin) followed by embolic particles, exploiting the HCC's exclusive arterial blood supply. Drug-eluting bead TACE (DEB-TACE) uses microspheres loaded with doxorubicin (DC Bead®) for sustained, controlled drug release with reduced systemic toxicity. Response is assessed by modified RECIST (mRECIST) at 4–6 weeks post-procedure. 4. Transarterial Radioembolization (TARE / Y-90): Administration of yttrium-90 microspheres (SIR-Spheres® or TheraSphere®) via hepatic arterial catheterization delivers targeted internal radiation to the tumor while largely sparing normal hepatic parenchyma. Particularly advantageous for tumors with portal vein tumor thrombus (PVTT) where TACE carries higher risk. Radiation segmentectomy with Y-90 can achieve ablative doses to single-segment tumors. 5. Radiofrequency Ablation (RFA) & Microwave Ablation (MWA): Percutaneous thermal ablation is preferred for HCC ≤3 cm, especially in patients with impaired liver function who cannot tolerate resection. RFA uses alternating electrical current to generate frictional heat (60–100°C), inducing coagulative necrosis with 3–5 cm ablation zones. MWA (915 MHz or 2.45 GHz systems) generates larger, more consistent ablation zones, is less susceptible to heat-sink effect from adjacent vessels, and completes ablation faster. Both are performed under real-time ultrasound or CT guidance, or via laparoscopic approach for anteriorly located tumors. 6. Stereotactic Body Radiation Therapy (SBRT): High-dose, hypofractionated external beam radiation (typically 36–54 Gy in 3–6 fractions) delivered with sub-millimeter precision using respiratory gating and image guidance (IGRT). Suitable for HCC not amenable to ablation or TACE, and increasingly used for portal vein tumor thrombus. Proton beam therapy (PBT), available at select centers, offers the dosimetric advantage of a Bragg peak — depositing maximal dose within the tumor while minimizing radiation to adjacent normal liver. SYSTEMIC THERAPY: 7. First-Line Immunotherapy + Anti-VEGF Combination: Atezolizumab (PD-L1 checkpoint inhibitor) + bevacizumab (anti-VEGF) — the IMbrave150 regimen — is the current preferred first-line treatment for advanced, unresectable HCC, demonstrating superior overall survival and progression-free survival versus sorafenib. Durvalumab + tremelimumab (STRIDE regimen) is an alternative first-line IO-IO combination. Pembrolizumab monotherapy is an option for patients with contraindications to bevacizumab (high variceal bleeding risk). 8. First-Line Tyrosine Kinase Inhibitors (TKIs): Sorafenib (multikinase inhibitor; RAF/VEGFR/PDGFR) and lenvatinib (VEGFR1-3/FGFR1-4 inhibitor) remain standard first-line options, particularly where IO-based therapy is contraindicated. Second-line agents include regorafenib, cabozantinib, and ramucirumab (for AFP ≥400 ng/mL). 9. Adjuvant Therapy Post-Resection/Ablation: Atezolizumab + bevacizumab is being evaluated in the adjuvant setting (IMbrave050 trial). Sorafenib adjuvant therapy demonstrated limited benefit in prior trials. Antiviral therapy (tenofovir/entecavir for HBV; direct-acting antivirals for HCV) is maintained throughout treatment to prevent viral reactivation and slow cirrhosis progression. ADVANCED BRIDGING AND DOWNSTAGING STRATEGIES: • Portal Vein Embolization (PVE) followed by Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) for patients with insufficient future liver remnant • Neoadjuvant TACE or ablation as a bridge to transplantation to prevent dropout on the waiting list • Downstaging protocols (TACE ± systemic therapy) for patients outside Milan criteria, targeting transplant eligibility
Recovery
PHASE 1 — PRE-ARRIVAL WORKUP (Weeks 1–3, from home country): • Patient submits medical records (imaging, pathology reports, lab work) to GAF Healthcare's clinical coordination team • GAF's oncology panel conducts a virtual MDT review and issues a detailed treatment recommendation within 48–72 hours • GAF assists with e-Medical visa application for India or UAE entry visa facilitation; visa processing typically takes 3–7 business days • Patient books flights; GAF arranges airport pickup, hospital-adjacent accommodation for the patient and one attendant PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (Days 1–4): • Day 1: Airport transfer, hotel check-in, hospital orientation • Days 2–3: Repeat or supplementary imaging if required (dynamic MRI liver, PET-CT); comprehensive blood panel (AFP, PIVKA-II, LFTs, coagulation profile, viral hepatology markers, ECHO for surgical/transplant candidates); ICG test; anesthesiology and hepatology consultation • Day 4: MDT Tumor Board convenes with patient-present consultation; final treatment plan confirmed; consent process completed PHASE 3 — TREATMENT (Variable by modality): For Hepatic Resection (Open or Robotic/Laparoscopic): • Day 5: Admission to hospital; pre-operative preparation (bowel prep, antibiotic prophylaxis, DVT prophylaxis stockings and LMWH) • Day 6: Surgery (4–8 hours); intraoperative blood salvage (Cell Saver); ICU admission post-operatively for hemodynamic monitoring • Days 7–10: ICU/HDU stay; nasogastric tube removal Day 1–2 post-op; drain management; early enteral nutrition initiated • Days 11–18: Step-down ward; progressive ambulation; liver function trend monitoring (bilirubin, INR, albumin); drain removal; staple/suture removal • Day 18–21: Discharge planning; oncology follow-up appointment scheduled For TACE / Y-90 TARE: • Day 5: Admission; pre-procedure hydration and antiemetic prophylaxis • Day 6: Procedure under conscious sedation or general anesthesia (1–2 hours); femoral or radial artery access; superselective catheterization under fluoroscopic and cone-beam CT guidance • Days 7–8: Post-embolization syndrome management (fever, pain, nausea — expected and self-limiting); IV analgesia, antiemetics; liver function and renal function monitoring • Day 9–10: Discharge; outpatient review scheduled for Week 6 mRECIST response assessment For Percutaneous Ablation (RFA/MWA): • Day 5: Admission; NPO from midnight • Day 6: Ablation procedure under IV sedation or general anesthesia (30–90 minutes); ultrasound or CT guidance; immediate post-procedural contrast CT to confirm ablation margin adequacy • Day 7–8: Observation; pain management; liver enzyme monitoring (transient ALT/AST elevation expected) • Day 8–9: Discharge PHASE 4 — IN-COUNTRY RECOVERY & SURVEILLANCE (Weeks 3–8): • Surgical patients rest at the arranged accommodation with daily nurse home-visits or outpatient clinic check-ups (wound care, drain site inspection, LFT trending) • Week 4–5 post-resection: Surgical site fully healed; sutures/staples removed; patient can ambulate independently; light diet tolerated • Week 6: First post-treatment imaging (dynamic MRI or CT) to assess treatment response (mRECIST for TACE; modified ablation zone assessment for RFA/MWA) • Week 6–8: Oncology review; systemic therapy initiation discussed if applicable; fit-to-fly assessment by treating surgeon/hepatologist • Comprehensive discharge summary, imaging CDs, pathology reports, and follow-up protocol provided to patient by GAF Healthcare coordinator PHASE 5 — RETURN HOME & LONG-TERM FOLLOW-UP: • Surveillance imaging every 3 months for first 2 years (dynamic MRI or 4-phase CT), then every 6 months — per AASLD/EASL guidelines • AFP and PIVKA-II monitoring at each follow-up • GAF Healthcare maintains telemedicine liaison with the treating team for ongoing remote consultation and report review
Risks to be aware of
Liver cancer treatment carries a range of procedure-specific and disease-related risks that all patients must understand prior to committing to a treatment pathway. For surgical resection, the most serious risk is post-hepatectomy liver failure (PHLF), defined by the International Study Group of Liver Surgery (ISGLS) criteria, which occurs in 1–9% of major resections and carries significant mortality risk; it is mitigated by rigorous preoperative assessment of future liver remnant volume and function. Bile leak (3–5%), post-operative hemorrhage, wound infection, pleural effusion, and venous thromboembolism (DVT/PE) are recognized complications. Perioperative mortality at high-volume hepatobiliary centers is typically less than 2–3%. For liver transplantation, primary graft non-function, hepatic artery thrombosis, biliary strictures, and acute/chronic rejection are organ-specific risks. Lifelong immunosuppression increases susceptibility to opportunistic infections and de-novo malignancies. In living-donor transplantation, donor morbidity (0.2–0.5% mortality risk to the donor) is an ethical and clinical consideration that is managed rigorously at accredited transplant centers. For TACE and TARE (Y-90), post-embolization syndrome — comprising fever, abdominal pain, nausea, and fatigue — is near-universal and typically self-limiting within 5–7 days. Non-target embolization with inadvertent treatment of normal hepatic parenchyma, cholecystitis, gastric ulceration, and radiation-induced liver disease (RILD) are less common but recognized risks. Hepatic decompensation post-TACE in patients with borderline liver reserve is a serious concern. For RFA and MWA, risks include bleeding (1–2%), bile duct injury leading to biloma or stricture, skin burn at the electrode site, pneumothorax for dome-of-liver lesions, and — rarely — tumor seeding along the needle tract (0.5%). For systemic therapy (atezolizumab + bevacizumab), immune-related adverse events (irAEs) — including immune-mediated hepatitis, pneumonitis, colitis, and endocrinopathies — require close monitoring and may necessitate corticosteroid management or drug discontinuation. Bevacizumab carries a risk of hypertension, proteinuria, thromboembolic events, and gastrointestinal perforation; it is contraindicated within 6 months of a significant bleeding event or in the presence of high-risk varices. Sorafenib and lenvatinib cause hand-foot skin reaction, hypertension, diarrhea, and fatigue as common class effects. All treatment decisions are made within the context of the patient's Child-Pugh/MELD score, ECOG performance status, and comorbidity profile. GAF Healthcare's partner centers operate dedicated hepatobiliary ICUs with 24/7 hepatologist and surgical cover to manage complications promptly.
Why GAF Healthcare
GAF Healthcare provides a fully integrated, concierge-level non-medical support system designed to eliminate logistical friction for international patients and their families. VISA ASSISTANCE: • India: GAF Healthcare's visa team assists patients with the e-Medical Visa application (Government of India portal), which permits an initial stay of 60 days with two extensions available, covering the full treatment and recovery period. We prepare the required hospital invitation letter, medical justification document, and coordinate with the embassy on the patient's behalf. Processing time is typically 3–7 business days. • UAE (Dubai / Abu Dhabi): Citizens of over 50 nationalities receive visa-free or visa-on-arrival access to the UAE for 30–90 days. For other nationalities, GAF Healthcare facilitates a medical treatment visa through the General Directorate of Residency and Foreigners Affairs (GDRFA) or the ICP, using letters from our DHA-licensed partner hospitals. The UAE also offers a renewable Medical Treatment Visa for extended stays. AIRPORT & GROUND TRANSFERS: • Private, air-conditioned vehicle transfers are arranged for all arrivals and departures, with a dedicated GAF coordinator meeting the patient at the arrivals hall — particularly important for post-operative patients with mobility restrictions. • Ambulance transfer service with medical escort is available for patients traveling in a clinically compromised state. ACCOMMODATION: • GAF Healthcare has negotiated preferential rates at hospital-adjacent serviced apartments and hotels (within 5–15 minutes of the treating hospital) that are suitable for patients and one accompanying attendant. Rooms are equipped with a kitchenette, and housekeeping is provided. • For transplant or major resection patients requiring extended stays, long-stay apartment options with nursing support are arranged. TRANSLATION & CULTURAL SUPPORT: • Dedicated medical interpreters fluent in Arabic, Russian, French, Swahili, Bangla, and other languages accompany patients to all clinical consultations, procedure-day briefings, and discharge planning sessions. • GAF Healthcare's patient coordinators are available 24/7 via WhatsApp, phone, and email throughout the in-country stay. MEDICAL RECORD & TELEMEDICINE CONTINUITY: • All medical records, imaging (DICOM files), pathology slides (digital), operative notes, and discharge summaries are collated in a secure digital patient file and shared with the patient's home country oncologist. • GAF Healthcare facilitates post-return telemedicine follow-up sessions between the patient and the treating oncologist for ongoing surveillance review.
Common questions about Liver Cancer Treatment
What is the cost of Liver Cancer Treatment in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after Liver Cancer Treatment?
What is the success rate of Liver Cancer Treatment, and what factors influence outcomes?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Liver Cancer Treatment in Dubai, UAE
Discover the Top Hospitals for Liver Cancer Treatment in Dubai, UAE
This page lists 3 accredited cancer care hospitals in Dubai, UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about liver cancer treatment in Dubai, UAE
How many cancer care hospitals are listed in Dubai, UAE?
How do you choose which hospitals to list?
How much does treatment cost in UAE?
Are there cancer care hospitals for this in other UAE cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for liver cancer treatment in Dubai, UAE.
Contact us to report an inaccuracy on this page.